About: Treatment with Class A CpG Oligodeoxynucleotides in Cats with Naturally Occurring Feline Parvovirus Infection: A Prospective Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment with Class A CpG Oligodeoxynucleotides in Cats with Naturally Occurring Feline Parvovirus Infection: A Prospective Study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Treatment with Class A CpG Oligodeoxynucleotides in Cats with Naturally Occurring Feline Parvovirus Infection: A Prospective Study
Creator	Lutz, Hans Hofmann-Lehmann, Regina Ferri, Filippo Rossi, Francesco Zini, Eric Meli, Marina Contiero, Barbara Coppola, Luigi Crinò, Chiara Callegari, Carolina Enache, Daniela Gerardi, Gabriele Kohan, Neda Porporato, Federico
Source	PMC
abstract	Feline parvovirus (FPV) causes severe gastroenteritis and leukopenia in cats; the outcome is poor. Information regarding specific treatments is lacking. Class A CpG oligodeoxynucleotides (CpG-A) are short single-stranded DNAs, stimulating type I interferon production. In cats, CpG-A induced an antiviral response in vivo and inhibited FPV replication in vitro. The aim was to prospectively investigate the effects of CpG-A on survival, clinical score, hematological findings, antiviral response (cytokines), viremia, and fecal shedding (real-time qPCR) in cats naturally infected with FPV. Forty-two FPV-infected cats were randomized to receive 100 µg/kg of CpG-A (n = 22) or placebo (n = 20) subcutaneously, on admission and after 48 h. Blood and fecal samples were collected on admission, after 1, 3, and 7 days. All 22 cats showed short duration pain during CpG-A injections. The survival rate, clinical score, leukocyte and erythrocyte counts, viremia, and fecal shedding at any time-point did not differ between cats treated with CpG-A (50%) and placebo (40%). Antiviral myxovirus resistance (Mx) gene transcription increased in both groups from day 1 to 3 (p = 0.005). Antibodies against FPV on admission were associated with survival in cats (p = 0.002). In conclusion, CpG-A treatment did not improve the outcome in cats with FPV infection. FPV infection produced an antiviral response.
has issue date	2020-06-12(xsd:dateTime)
bibo:doi	10.3390/v12060640
bibo:pmid	32545689
has license	cc-by
sha1sum (hex)	f5fea0f1b54b9bab5a0db265611199ffe5a60295
schema:url	https://doi.org/10.3390/v12060640
resource representing a document's title	Treatment with Class A CpG Oligodeoxynucleotides in Cats with Naturally Occurring Feline Parvovirus Infection: A Prospective Study
has PubMed Central identifier	PMC7354499
has PubMed identifier	32545689
schema:publication	Viruses
resource representing a document's body	covid:f5fea0f1b54b9bab5a0db265611199ffe5a60295#body_text
is schema:about of	named entity 'survival rate' named entity 'cats' named entity 'severe' named entity 'shedding' named entity 'specific' named entity 'injections' named entity 'vivo' named entity 'Study' named entity 'Cats' named entity 'PAIN' named entity 'INFORMATION' named entity 'ERYTHROCYTE' named entity 'COLLECTED' named entity 'ANTIBODIES' named entity 'RECEIVE' named entity 'CONCLUSION' named entity 'CATS' named entity 'MYXOVIRUS' covid:arg/f5fea0f1b54b9bab5a0db265611199ffe5a60295 named entity 'cats' named entity 'response' named entity 'response' named entity 'FPV' named entity 'viremia' named entity 'replication' named entity 'gene' named entity 'randomized' named entity 'Antibodies' named entity 'gene transcription' named entity 'hematological' named entity 'CpG' named entity 'FPV' named entity 'antiviral' named entity 'CpG' named entity 'erythrocyte' named entity 'CpG' named entity 'antiviral' named entity 'CpG ODN' named entity 'FeLV' named entity 'false positives' named entity 'uracil-DNA glycosylase' named entity 'immunofluorescence assay' named entity 'FIV' named entity 'CpG ODN' named entity 'Body weight' named entity 'ANOVA' named entity 'Applied Biosystems' named entity 'domestic shorthair' named entity 'viral RNA' named entity 'provirus' named entity 'natural killer cells' named entity 'maternal antibodies' named entity 'cytotoxicity' named entity 'transcription' named entity 'feline leukemia virus' named entity 'type 1' named entity 'time-point' named entity 'infection' named entity 'Cytokine' named entity 'Applied Biosystems' named entity 'FeLV' named entity 'parvovirus' named entity 'double-blinded' named entity 'placebo' named entity 'CpG ODN' named entity 'CpG ODN' named entity 'FPV' named entity 'immunofluorescence assays'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software